Texas A&M Health researchers have engineered a novel molecular safety switch that leverages artificial intelligence and caffeine to precisely regulate engineered cells in future therapies. Published in the Journal of the American Chemical Society, the platform, designated CODS (caffeine-operated dissociation system), represents a significant advancement in programmable medicine by enabling researchers to rapidly pause or reverse cellular responses on demand. Led by Yubin Zhou, MD, PhD, director of the Center for Translational Cancer Research at the Texas A&M Health Institute of Biosciences and Technology, the research team developed a synthetic protein binder that functions as a molecular clasp. Unlike earlier caffeine-responsive systems designed to pull proteins together, CODS utilizes caffeine to force engineered proteins apart. In the absence of the compound, the clasp remains sealed, maintaining cellular activity. Upon caffeine introduction, the proteins dissociate, effectively halting the targeted pathway. This architecture provides clinicians with a reversible control mechanism analogous to a brake, rather than an accelerator. The design process relied heavily on artificial intelligence and high-performance computing. Graduate researcher Brendan McKee led the AI-guided protein modeling and computational screening, while Tatsuki Nonomura directed molecular engineering and live-cell validation. The team utilized the Texas A&M High Performance Research Computing infrastructure to execute intensive AI-driven workflows, accelerating the transition from computational design to functional biological validation. The resulting system demonstrates rapid response times, operates at low caffeine concentrations, and maintains reversibility across multiple activation cycles. Experimental validation established CODS efficacy across three distinct biological domains. First, the system successfully modulated engineered gene circuits, where caffeine addition triggered immediate protein dissociation and sharply reduced target gene expression. Second, researchers integrated the switch into a programmed cell death pathway, demonstrating that caffeine could induce pyroptosis, offering new avenues for studying inflammatory responses. Most notably, the team applied CODS to chimeric antigen receptor T-cells, a widely used immunotherapy for blood cancers. By splitting the CAR structure, the researchers created a conditional activation system where caffeine temporarily suppresses therapeutic cell activity. This capability directly addresses a critical clinical challenge: mitigating severe immune overactivation without permanently eliminating engineered cells. The breakthrough underscores the expanding utility of computational biology in therapeutic design. Zhou emphasized that caffeine serves strictly as a standardized signaling molecule rather than a therapeutic agent, highlighting a broader strategy of programming cells to respond to familiar, clinically approved small molecules. While CODS requires further evaluation in animal models and disease-relevant therapeutic contexts, it establishes a reproducible framework for designing controllable biotherapeutics. By synthesizing AI-driven protein architecture, advanced computational resources, and targeted chemical triggers, the Texas A&M team has introduced a scalable methodology for enhancing the safety and responsiveness of next-generation cell therapies.